A narrative review on sacubitril/valsartan and ventricular arrhythmias

Sacubitril/valsartan, the first angiotensin receptor neprilysin inhibitor approved by the Food and Drug Administration for marketing, has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms in patients with chronic heart failure with a reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Zhaoyang, Zhang, Meiwei, Zhang, Qian, Gong, Linan, Wang, Xiangyu, Wang, Zanzan, Gao, Ming, Zhang, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259167/
https://www.ncbi.nlm.nih.gov/pubmed/35801732
http://dx.doi.org/10.1097/MD.0000000000029456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259167/
https://www.ncbi.nlm.nih.gov/pubmed/35801732
http://dx.doi.org/10.1097/MD.0000000000029456

Ejemplares similares